In a landmark decision, President Donald Trump has signed an executive order that reclassifies cannabis, marking a pivotal shift in the legal landscape surrounding the substance. The source reports that this change is expected to have far-reaching implications for medical research and the hemp industry.
Reclassification of Cannabis
The executive order reclassifies cannabis from Schedule I to Schedule III of the Controlled Substances Act, a move that acknowledges the accepted medical uses of cannabis. This reclassification will facilitate increased research into medical marijuana and cannabidiol, potentially leading to new treatments and therapies.
Impact on the Hemp Industry
Additionally, the order aims to bolster the hemp industry, which has encountered significant hurdles due to recent legislative changes. The decision comes on the heels of a review by the Biden administration, which highlighted scientific evidence supporting the medical benefits of cannabis. This shift not only reflects changing attitudes towards cannabis but also opens the door for further advancements in its medical applications.
Following the recent executive order on cannabis reclassification, the US Supreme Court is set to hear a significant case regarding tariffs imposed by former President Trump. For more details, see tariffs case.
